BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

278 related articles for article (PubMed ID: 24167321)

  • 21. Reversal of CPT-11 resistance of lung cancer cells by adenovirus-mediated gene transfer of the human carboxylesterase cDNA.
    Kojima A; Hackett NR; Crystal RG
    Cancer Res; 1998 Oct; 58(19):4368-74. PubMed ID: 9766666
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Isolation and partial characterization of a cDNA encoding a rabbit liver carboxylesterase that activates the prodrug irinotecan (CPT-11).
    Potter PM; Pawlik CA; Morton CL; Naeve CW; Danks MK
    Cancer Res; 1998 Jun; 58(12):2646-51. PubMed ID: 9635592
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Human Neural Stem Cells Overexpressing a Carboxylesterase Inhibit Bladder Tumor Growth.
    Choi SS; Chi BH; Chang IH; Kim KD; Lee SR; Kim SU; Lee HJ
    Mol Cancer Ther; 2016 Jun; 15(6):1201-7. PubMed ID: 27009215
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Intracellular conversion of irinotecan to its active form, SN-38, by native carboxylesterase in human non-small cell lung cancer.
    Ohtsuka K; Inoue S; Kameyama M; Kanetoshi A; Fujimoto T; Takaoka K; Araya Y; Shida A
    Lung Cancer; 2003 Aug; 41(2):187-98. PubMed ID: 12871782
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Brain tumor oncolysis with replication-conditional herpes simplex virus type 1 expressing the prodrug-activating genes, CYP2B1 and secreted human intestinal carboxylesterase, in combination with cyclophosphamide and irinotecan.
    Tyminski E; Leroy S; Terada K; Finkelstein DM; Hyatt JL; Danks MK; Potter PM; Saeki Y; Chiocca EA
    Cancer Res; 2005 Aug; 65(15):6850-7. PubMed ID: 16061668
    [TBL] [Abstract][Full Text] [Related]  

  • 26. CPT-11 in human colon-cancer cell lines and xenografts: characterization of cellular sensitivity determinants.
    Jansen WJ; Zwart B; Hulscher ST; Giaccone G; Pinedo HM; Boven E
    Int J Cancer; 1997 Jan; 70(3):335-40. PubMed ID: 9033637
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effects of genetically engineered stem cells expressing cytosine deaminase and interferon-beta or carboxyl esterase on the growth of LNCaP rrostate cancer cells.
    Yi BR; Hwang KA; Kim YB; Kim SU; Choi KC
    Int J Mol Sci; 2012 Sep; 13(10):12519-32. PubMed ID: 23202910
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Intracellular inhibition of carboxylesterases by benzil: modulation of CPT-11 cytotoxicity.
    Hyatt JL; Tsurkan L; Wierdl M; Edwards CC; Danks MK; Potter PM
    Mol Cancer Ther; 2006 Sep; 5(9):2281-8. PubMed ID: 16985062
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Hypoxia-targeted over-expression of carboxylesterase as a means of increasing tumour sensitivity to irinotecan (CPT-11).
    Matzow T; Cowen RL; Williams KJ; Telfer BA; Flint PJ; Southgate TD; Saunders MP
    J Gene Med; 2007 Apr; 9(4):244-52. PubMed ID: 17397102
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Intravascular delivery of neural stem cell lines to target intracranial and extracranial tumors of neural and non-neural origin.
    Brown AB; Yang W; Schmidt NO; Carroll R; Leishear KK; Rainov NG; Black PM; Breakefield XO; Aboody KS
    Hum Gene Ther; 2003 Dec; 14(18):1777-85. PubMed ID: 14670128
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Combination therapy with irinotecan and protein kinase C inhibitors in malignant glioma.
    Chen TC; Su S; Fry D; Liebes L
    Cancer; 2003 May; 97(9 Suppl):2363-73. PubMed ID: 12712458
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Proficient metabolism of irinotecan by a human intestinal carboxylesterase.
    Khanna R; Morton CL; Danks MK; Potter PM
    Cancer Res; 2000 Sep; 60(17):4725-8. PubMed ID: 10987276
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pharmacokinetic study of neural stem cell-based cell carrier for oncolytic virotherapy: targeted delivery of the therapeutic payload in an orthotopic brain tumor model.
    Thaci B; Ahmed AU; Ulasov IV; Tobias AL; Han Y; Aboody KS; Lesniak MS
    Cancer Gene Ther; 2012 Jun; 19(6):431-42. PubMed ID: 22555507
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Gene-directed enzyme prodrug therapy for osteosarcoma: sensitization to CPT-11 in vitro and in vivo by adenoviral delivery of a gene encoding secreted carboxylesterase-2.
    Oosterhoff D; Witlox MA; van Beusechem VW; Haisma HJ; Schaap GR; Bras J; Kruyt FA; Molenaar B; Boven E; Wuisman PI; Pinedo HM; Gerritsen WR
    Mol Cancer Ther; 2003 Aug; 2(8):765-71. PubMed ID: 12939466
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A comparative study of neural and mesenchymal stem cell-based carriers for oncolytic adenovirus in a model of malignant glioma.
    Ahmed AU; Tyler MA; Thaci B; Alexiades NG; Han Y; Ulasov IV; Lesniak MS
    Mol Pharm; 2011 Oct; 8(5):1559-72. PubMed ID: 21718006
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The timing of neural stem cell-based virotherapy is critical for optimal therapeutic efficacy when applied with radiation and chemotherapy for the treatment of glioblastoma.
    Tobias AL; Thaci B; Auffinger B; Rincón E; Balyasnikova IV; Kim CK; Han Y; Zhang L; Aboody KS; Ahmed AU; Lesniak MS
    Stem Cells Transl Med; 2013 Sep; 2(9):655-66. PubMed ID: 23926209
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Local enzymatic hydrolysis of an endogenously generated metabolite can enhance CPT-11 anticancer efficacy.
    Prijovich ZM; Chen KC; Roffler SR
    Mol Cancer Ther; 2009 Apr; 8(4):940-6. PubMed ID: 19372567
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Neural stem cell-mediated enzyme/prodrug therapy for glioma: preclinical studies.
    Aboody KS; Najbauer J; Metz MZ; D'Apuzzo M; Gutova M; Annala AJ; Synold TW; Couture LA; Blanchard S; Moats RA; Garcia E; Aramburo S; Valenzuela VV; Frank RT; Barish ME; Brown CE; Kim SU; Badie B; Portnow J
    Sci Transl Med; 2013 May; 5(184):184ra59. PubMed ID: 23658244
    [TBL] [Abstract][Full Text] [Related]  

  • 39. CPT-11 converting carboxylesterase and topoisomerase activities in tumour and normal colon and liver tissues.
    Guichard S; Terret C; Hennebelle I; Lochon I; Chevreau P; Frétigny E; Selves J; Chatelut E; Bugat R; Canal P
    Br J Cancer; 1999 May; 80(3-4):364-70. PubMed ID: 10408839
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Overexpression of carboxylesterase-2 results in enhanced efficacy of topoisomerase I inhibitor, irinotecan (CPT-11), for multiple myeloma.
    Yano H; Kayukawa S; Iida S; Nakagawa C; Oguri T; Sanda T; Ding J; Mori F; Ito A; Ri M; Inagaki A; Kusumoto S; Ishida T; Komatsu H; Inagaki H; Suzuki A; Ueda R
    Cancer Sci; 2008 Nov; 99(11):2309-14. PubMed ID: 18771527
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.